Active, not recruitingPhase 3NCT04608318
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- German CLL Study Group
- Principal Investigator
- Othman Al-Sawaf, Dr. med.German CLL Study Group
- Intervention
- Ibrutinib(biological)
- Enrollment
- 897 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- LKH-Universtitätsklinikum Graz, Graz, Austria
- Landeskrankenhaus - Universitätskliniken Innsbruck, Innsbruck, Austria
- Medizinische Universität Wien, Vienna, Austria
- Hanusch Krankenhaus, Vienna, Austria
- Wiener Gesundheitsverbund Klinik Ottakring, Vienna, Austria
- Algemeen Ziekenhuis St. Jan, Bruges, Belgium
- Universitair Ziekenhuis Leuven, Leuven, Belgium
- Algemeen Ziekenhuis Delta, Roeselare, Belgium
- Aalborg Universitetshospital, Aalborg, Denmark
- Aarhus Universitetshospital, Aarhus, Denmark
- Rigshospitalet, Copenhagen, Denmark
- Sydvestjysk Sygehus Esbjerg, Esbjerg, Denmark
- Regionshospitalet Holstebro, Holstebro, Denmark
- Odense Universitetshospital, Odense, Denmark
- Zealand University Hospital, Roskilde, Denmark
- +15 more locations on ClinicalTrials.gov
Collaborators
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) · Nordic CLL Study Group (NCLLSG) · Swiss Group for Clinical Cancer Research (SAKK) · Cancer Trials Ireland · Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) · Grupo Español de Leucemia Linfocítica Crónica (GELLC) · The Israeli CLL Study Group (ICLLSG) · Janssen Pharmaceutica N.V., Belgium · AbbVie · Hoffmann-La Roche
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04608318 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn